DarioHealth Corp. (NASDAQ:DRIO) stock recently located move of -67.35% off 52-week high price and identified change of 21.03% away from 52-week low price. DRIO stock has been recorded -4.15% away from 50 day moving average and -28.22% away from 200 day moving average. Moving closer, we can see that shares have been trading -0.94% off 20-day moving average. It has market worth of $14.54M.
Global digital therapeutics innovator, DarioHealth Corp. (NASDAQ:DRIO), reported a joint marketing agreement with Glytec, the market leader and pioneer of insulin titration solutions for use across the full continuum of care. The agreement allows DarioHealth’s smart glucose meter (part of the Dario Blood Glucose Monitoring System) to transmit information to Glytec’s Glucommander™ Outpatient software-as-a-medical-device.
Blood glucose data from the Dario Blood Glucose Monitoring System, automatically sent to the Cloud in real-time, will be seamlessly imported to Glucommander Outpatient™ and utilized in conjunction with other clinical data to formulate personalized insulin dose recommendations. The connected care model supports virtual insulin titration for outpatients with diabetes.
“The Dario Blood Glucose Monitoring System is growing in popularity among people with both Type 1 and Type 2 diabetes, and we are pleased to be able to add DarioHealth to our best-in-class network of connected device partners,” said Bob Leonard, Glytec’s President and Chief Executive Officer. “Glytec doesn’t make devices, we make devices BETTER by adding the missing element, which is insulin titration. There is little that can be done to achieve and sustain significant A1c improvements with data alone, but by making that data actionable and making timely insulin dose adjustments, we see average reductions in A1c of 2.7% points and higher over 12 months.”
The Dario Blood Glucose Monitoring System combines five essential tools to simplify diabetes management: (1) a sleek, all-in-one smart glucose meter, (2) a personal diabetes progress monitor, (3) on-demand data sharing, (4) emergency hypoglycemia alerts with GPS locator, and (5) a carb counting tool.
“Glytec will benefit from real-time, accurate blood glucose data to provide insulin titration decision support, and we are convinced that the Dario Blood Glucose Monitoring System will be a more complete solution when paired with Glucommander™ Outpatient,” said Erez Raphael, DarioHealth’s Chief Executive Officer. “We believe that people with diabetes need this synergy to be most successful in managing their diabetes.”
The Healthcare sector company, DarioHealth Corp. noticed change of -5.77% to $0.7 along volume of 154991 shares in recent session compared to an average volume of 65.78K. The stock observed return of 3.74% in 5 days trading activity. The stock was at -8.26% over one month performance. DRIO’s shares are at -16.38% for the quarter and driving a -49.86% return over the course of the past year and is now at -9.54% since this point in 2018.
The average volatility for the week at 19.05% and for month was at 10.87%. There are 20.71M shares outstanding and 12.78M shares are floated in market. Right now the stock beta is -1.27.